EMBARK BIOTECH JOINS BII
September 1st, 2021
Embark Biotech joined the Creation House Program at the BioInnovation Institute with the aim of advancing our lead program, EMB1, through preclinical development. EMB1 is a novel mechanism-of-action for controlling food intake and increasing energy expenditure with potential to treat a wide range of metabolic disorders. In the first half of 2022, we will begin seeking funding opportunities for a series A round to achieve clinical proof-of-concept in genetic forms of obesity.
EMBARK GETS INNOBOOSTER GRANT
October 15th, 2021
Embark Biotech was awarded an InnoBooster grant from InnovationsFonden to advance the nonclinical development of the EMB1 program.